That was an amazing post Buckeyes ( this one was good too). Great discussion by all in this thread. As iconoclast stated "The discussion is very normal, IMHO.  We have an almost binary outcome.  So naturally, us human beings will start coming up with all kinds of nightmare & heavenly scenarios." I personally feel that Buckeyes' perspective on how milestones like positive top-line and full data may affect share price is on the conservative end of the spectrum. Keep in mind that Resverlogix, BETonMACE and apabetalone are flying way under the radar and/or most are expecting BETonMACE failure based upon past history. If and when BETonMACE proves the doubters wrong with positive top-line data and Resverlogix/BETonMACE/apabetalone finally get mainstream attention, then this quiet, little known story full of caution and skepticism could turn into an all star, in the spotlight, gamechanging breakthrough therapy/company. For these reasons, positive top-line, even if it is only a general statement of successfully meeting the primary MACE endpoint, without any reveal of %RRR, could propel this stock to at least where Amarin now sits at around a 6 billion US market cap range. That's about $30 US per share for Resverlogix right now. And this doesn't include any additional valuation from positive renal or cognition sub-studies. Of course, this opinion is on the other side of the spectrum from Buckeyes', but it is importantly to keep both extremes (and all other possibilities in between) in mind. The market can be irrational, emotional and fickle. This is going to be one wild ride over the rest of the year not knowing where this roller coaster is taking us. Good luck to all.

BearDownAZ